• New applications in the bioprocess and pharmaceutical industry
• IX process more efficient than precipitation processes
Cologne, December 28, 2020 – Specialty chemicals company LANXESS is extending its portfolio of products in the consumer care segment to include the new Lewatit PH 1074 HEP. In addition to the decolorization of fermentation broths and sugar, it is particularly suited to the purification and intermediate storage of heparin. As one of the leading manufacturers of ion exchangers, LANXESS intends to use this innovative product to tap new customers in the pharmaceutical and bioprocessing industry and further strengthen its market position.
The macroporous, strongly basic anion exchange resin that meets food quality standards is based on a cross-linked polyacrylate. It has a special pore structure and resin matrix, which has been exclusively developed for the capture of highly molecular compounds.
Lewatit PH 1074 HEP is suitable for the treatment and purification of products derived from biomass, as it supports the reliable capture and removal of organic substances with a high molecular weight. This means that liquid sugar syrups or complex process solutions such as fermentation broths, for example, can be purified and treated.
Ion exchange results in high heparin yield, activity and purity
Sugar polymer heparin is used in medicine to prevent blood coagulation and venous thrombosis and is also applied as anticoagulant, for example, during heart surgery and dialysis. Heparin is typically purified with ion exchange resins, as this produces a higher yield, activity and purity of heparin and similar end products in comparison with precipitation processes for purification.
The methods used in the commercial production of pharmaceutical heparin are closely guarded operational secrets. All start with the collection of pig intestines from slaughterhouses, followed by the separation of the mucosal tissues. This is then broken down with enzymes in order to release heparin and polysaccharide derivatives.
Lewatit PH 1074 HEP helps extract the heparin from this complex mixture and then purify it. The ion exchanger can also be used to stabilize the heparin for transport and storage, which prevents the sugar polymer from breaking down.
The macroporous structure and special polymer matrix of the new
Lewatit PH 1074 HEP help achieve optimum adsorption capacity and desorption properties. This is extremely advantageous in the recovery of high-molecular hydrophilic anionic organic substances, which, for example, are extracted from fermentation broths in the same way as heparin and other glycosaminoglycans (GAGs).
Following the successful isolation and pre-purification of the heparin by the Lewatit PH 1074 HEP, further purification steps are carried out in order to produce heparin that meets pharmaceutical quality standards. This includes the removal of residual peptides and nucleotides, viruses and bacterial endotoxins, which can be achieved by means of bleaching, acid washing and caustic treatment and oxidation for virus inactivation as well as alcohol precipitation.
Comprehensive service around the globe
The Liquid Purification Technologies business unit provides support during the validation process for the approval of Lewatit PH 1074 HEP in customer production processes with a comprehensive technical support package. The new ion exchanger is food-safe (EU Regulation No. 1935/2004), halal, kosher, non-GMO and free from allergens, heavy metals and TSE/BSE. More detailed information can be found at https://lpt.lanxess.de/.
About LANXESS:
LANXESS is a leading specialty chemicals company with sales of EUR 6.8 billion in 2019. The company currently has about 14,400 employees in 33 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.
Forward-Looking Statements
This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.
Information for editors:
All LANXESS news releases and their accompanying photos can be found at http://press.lanxess.com. Recent photos of the Board of Management and other LANXESS image material are available at http://photos.lanxess.com.
You can find further information concerning LANXESS chemistry in our WebMagazine at http://webmagazine.lanxess.com
Follow us on Twitter, Facebook, Linkedin and YouTube:
http://www.twitter.com/LANXESS
http://www.facebook.com/
No comments:
Post a Comment